Compare SCVL & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCVL | CTNM |
|---|---|---|
| Founded | 1978 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 551.6M | 507.0M |
| IPO Year | 1994 | 2024 |
| Metric | SCVL | CTNM |
|---|---|---|
| Price | $16.89 | $12.19 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $19.80 |
| AVG Volume (30 Days) | ★ 288.6K | 232.9K |
| Earning Date | 03-26-2026 | 03-05-2026 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $1,202,885,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.80 | ★ N/A |
| Revenue Growth | ★ 2.30 | N/A |
| 52 Week Low | $15.21 | $3.35 |
| 52 Week High | $26.54 | $16.33 |
| Indicator | SCVL | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 28.67 | 37.68 |
| Support Level | $16.79 | $10.39 |
| Resistance Level | $18.37 | $13.18 |
| Average True Range (ATR) | 0.79 | 1.17 |
| MACD | -0.34 | -0.30 |
| Stochastic Oscillator | 1.56 | 4.29 |
Shoe Carnival Inc is a family footwear retailer that offers a broad assortment of dress, casual, and athletic footwear for men, women, and children with an emphasis on national name brands such as Nike, Skechers, Adidas, Puma, HEYDUDE, Converse, Vans, and Crocs. The company operates its business as one reportable segment based on the similar nature of products sold; merchandising, distribution, and marketing processes involved; target customers; and economic characteristics of stores and e-commerce platforms. Its bricks-first, omnichannel approach provides customers easy access to a wide assortment of branded footwear for work, athletics, daily activities, and special events via a choice of delivery channels.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.